




Biological Sex Modulates The Effects of The Immunoregulatory Fibrinogen-like Protein 2 Molecule on Alloimmunity

Presenter: Christina Lam

The Presenter Has no Financial Conflict to Disclose




Organized in partnership with











Biological Sex Modulates The Effects of The Immunoregulatory Fibrinogen-

like Protein 2 Molecule on Alloimmunity

Christina Lam, Sajad Moshkelgosha, Nadia Sachewsky, Stephen Juvet

Latner Thoracic Research Laboratories, UHN, Toronto, Ontario, Canada


Introduction

- The effects of sex differences on patients' outcome post-transplant remain poorly understood and understudied.
- o We know that females tend to mount more robust immune responses compared to males due to estrogen in the former and androgen in the latter.
- o The immunoregulatory fibrinogen-like protein 2 (fgl2) molecule, holds potential as tolerizing therapy.

Hypothesis

Fgl2's effect on the allograft response is sex dependent.


Method




- o in vitro: T cell isolation & activation
- o *in vivo*: Adoptive T cell transfer into Rag^{-/-} recipients (T cell-deficient), followed by a skin graft from Balb/c donor
- Both cells and graft donors were matched to the recipients' sex

Results

Biological sex influences Fgl2's regulation on the rejection kinetics of skin grafts






Survival curves of all four groups. P-value based on Log-rank Mantel-Cox test. MST = median survival time.



□ o' fgl2-/- T cells 3 undefined

- Intrinsic expression of Fgl2 in T cells downregulates the proliferation of CD4+ cells in vitro; this effect is not observed in female T cells
- Although in vivo data showed that fgl2 expression from T cells did not affect graft rejection, female T cells rejected Balb/c grafts faster than male T cells.
- This suggests that T cell extrinsic fgl2 in the Rag^{/-} environment may have contributed to slowing graft rejection mediated by male T cells.

3 Results



Proliferation of male and female CD4+ (**p= 0.014, ***p= 0.001) and CD8+ (*p=0.0145) T cells from either fgl2+/+ or fgl2-/- mice. Statistics obtained from 2way ANOVA.

Skin graft on *Rag*^{-/-} recipients of *fgl2*+/+ and *fgl2*-/- T cells at approx. 1 month and 2 months PO.